Ibrutinib/ibrutinib medical insurance reimbursement time

Ibrutinib/Ibrutinib is an anti-tumor agent and a Bruton's tyrosine kinase inhibitor (BTK), indicated for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM) and chronic graft-versus-host disease (cGVHD).

BTK is an important signaling molecule of the B-cell antigen receptor (BCR) pathway and plays a role in the pathogenesis of several B-cell malignancies, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and chronic lymphocytic leukemia (CLL). Preclinical studies have shown that ibrutinib can effectively inhibit malignant B cell proliferation and survival in vivo as well as cell migration and matrix adhesion in vitro. In early clinical studies, the activity of ibrutinib was described as including a rapid reduction in lymphadenopathy accompanied by transient lymphocytosis, suggesting that the drug may have a direct effect on factors in cell homing or migration into the tissue microenvironment. Ibrutinib has also been reported to reduce the chemotaxis of chronic lymphocytic leukemia cells to the chemokines CXCL12 and CXCL13 and inhibit cell adhesion after stimulating the B cell receptor (BCR).

Ibrutinib has been included in the scope of medical insurance reimbursement. The specific reimbursement time usually depends on the medical insurance policy and reimbursement process of the patient's region. Generally speaking, after purchasing ibrutinib, patients need to submit a reimbursement application to the local medical insurance agency with the doctor's prescription, drug purchase invoice, personal medical insurance card and other relevant information. After the review is correct, the medical insurance institution will reimburse according to the prescribed process and time.